Unicycive Therapeutics, Inc. (UNCY)

Unicycive Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	0.68	0.95	-	-
Revenue Growth (YoY)	-	-29.02%	-	-	-
Gross Profit	-	0.68	0.95	-	-
Selling, General & Admin	12.1	8.55	6.57	2.9	1.01
Research & Development	20.01	12.9	12.44	6.08	1.02
Operating Expenses	32.12	21.45	19	8.98	2.02
Operating Income	-32.12	-20.77	-18.05	-8.98	-2.02
Interest Expense	-0.07	-0.08	-0.01	-0.63	-0.24
Interest & Investment Income	1.26	0.62	-	-	-
Other Non Operating Income (Expenses)	-5.8	-10.3	-	-	-
EBT Excluding Unusual Items	-36.73	-30.54	-18.06	-9.61	-2.26
Other Unusual Items	-	-	-	-0.41	-
Pretax Income	-36.73	-30.54	-18.06	-10.02	-2.26
Net Income	-36.73	-30.54	-18.06	-10.02	-2.26
Preferred Dividends & Other Adjustments	1.1	0.87	-	-	-
Net Income to Common	-37.82	-31.41	-18.06	-10.02	-2.26
Shares Outstanding (Basic)	67	25	15	12	8
Shares Outstanding (Diluted)	67	25	15	12	8
Shares Change (YoY)	172.97%	62.98%	28.96%	37.37%	4.68%
EPS (Basic)	-0.56	-1.28	-1.20	-0.86	-0.27
EPS (Diluted)	-0.56	-1.28	-1.20	-0.86	-0.27
Free Cash Flow	-28.65	-18.3	-15.65	-5.8	-1.46
Free Cash Flow Per Share	-0.43	-0.75	-1.04	-0.50	-0.17
Gross Margin	-	100.00%	100.00%	-	-
Operating Margin	-	-3077.63%	-1898.21%	-	-
Profit Margin	-	-4653.48%	-1898.84%	-	-
Free Cash Flow Margin	-	-2710.37%	-1645.95%	-	-
EBITDA	-32.1	-20.77	-18.05	-8.98	-
D&A For EBITDA	0.02	0.01	0.01	0	-
EBIT	-32.12	-20.77	-18.05	-8.98	-2.02

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q